Genomic alterations in PDE genes or the biochemical inhibition of PDE function can sensitize NSCLC to PMX in vitro, independently of lung cancer histology (adenocarcinoma (AD) or squamous-cell carcinoma (SCC)). This evidence concerns the gene ALDH7A1 and lung cancer.